BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16713073)

  • 1. Loss of promyelocytic leukemia protein in human gastric cancers.
    Lee HE; Jee CD; Kim MA; Lee HS; Lee YM; Lee BL; Kim WH
    Cancer Lett; 2007 Mar; 247(1):103-9. PubMed ID: 16713073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of the promyelocytic leukemia protein in gastric cancer: implications for IP-10 expression and tumor-infiltrating lymphocytes.
    Kim HJ; Song DE; Lim SY; Lee SH; Kang JL; Lee SJ; Benveniste EN; Choi YH
    PLoS One; 2011; 6(10):e26264. PubMed ID: 22022583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.
    Bernardi R; Guernah I; Jin D; Grisendi S; Alimonti A; Teruya-Feldstein J; Cordon-Cardo C; Simon MC; Rafii S; Pandolfi PP
    Nature; 2006 Aug; 442(7104):779-85. PubMed ID: 16915281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promyelocytic leukemia protein enhances apoptosis of gastric cancer cells through Yes-associated protein.
    Xu Z; Chen J; Shao L; Ma W; Xu D
    Tumour Biol; 2015 Sep; 36(10):8047-54. PubMed ID: 25971581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation.
    Cabrera CM; Jiménez P; Concha A; Garrido F; Ruiz-Cabello F
    Tissue Antigens; 2004 May; 63(5):446-52. PubMed ID: 15104675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma.
    Xia M; Zhang JQ; Shen YQ; Xu LH; Chen AQ; Miao FQ; Xie W
    Tissue Antigens; 2007 Oct; 70(4):272-82. PubMed ID: 17767548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of the tumor suppressor PML in human cancers of multiple histologic origins.
    Gurrieri C; Capodieci P; Bernardi R; Scaglioni PP; Nafa K; Rush LJ; Verbel DA; Cordon-Cardo C; Pandolfi PP
    J Natl Cancer Inst; 2004 Feb; 96(4):269-79. PubMed ID: 14970276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.
    Herzer K; Weyer S; Krammer PH; Galle PR; Hofmann TG
    Cancer Res; 2005 Dec; 65(23):10830-7. PubMed ID: 16322229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of promyelocytic leukaemia protein in lung carcinomas and clinical significance thereof].
    Zhao ZL; Huang QY; Xu S; Zhang L; Zhao HR
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(47):3362-6. PubMed ID: 17313836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
    Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
    Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7.
    Bao-Lei T; Zhu-Zhong M; Yi S; Jun-Jie Q; Yan D; Hua L; Bin L; Guo-Wei Z; Zhi-Xian S
    J Cell Biochem; 2006 Feb; 97(3):561-71. PubMed ID: 16215989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of PML in carcinogenesis of laryngocarcinoma and nasopharyngeal carcinoma].
    Chen W; Yao W; Chen S; Xiao B; Tao Z
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Feb; 21(3):128-31. PubMed ID: 17441430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Interaction and Docking Studies Indicate a New Mechanism for PML Dysfunction in Gastric Cancer and Suggest Imatinib as a Drug to Restore Function.
    Imani-Saber Z; Ghafouri-Fard S
    Asian Pac J Cancer Prev; 2015; 16(12):5005-6. PubMed ID: 26163631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic PML function in TGF-beta signalling.
    Lin HK; Bergmann S; Pandolfi PP
    Nature; 2004 Sep; 431(7005):205-11. PubMed ID: 15356634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CK2 and PML: regulating the regulator.
    Lallemand-Breitenbach V; de Thé H
    Cell; 2006 Jul; 126(2):244-5. PubMed ID: 16873055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy.
    Shishido-Hara Y; Higuchi K; Ohara S; Duyckaerts C; Hauw JJ; Uchihara T
    J Neuropathol Exp Neurol; 2008 Apr; 67(4):299-308. PubMed ID: 18379438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective activation of NFAT by promyelocytic leukemia protein.
    Lo YH; Wu CC; Shih HM; Lai MZ
    Oncogene; 2008 Jun; 27(27):3821-30. PubMed ID: 18246125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promyelocytic leukemia-nuclear body formation is an early event leading to retinoic acid-induced differentiation of neuroblastoma cells.
    Delaune A; Corbière C; Benjelloun FD; Legrand E; Vannier JP; Ripoll C; Vasse M
    J Neurochem; 2008 Jan; 104(1):89-99. PubMed ID: 17986232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a tumour suppressor network opposing nuclear Akt function.
    Trotman LC; Alimonti A; Scaglioni PP; Koutcher JA; Cordon-Cardo C; Pandolfi PP
    Nature; 2006 May; 441(7092):523-7. PubMed ID: 16680151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
    Janssen K; Hofmann TG; Jans DA; Hay RT; Schulze-Osthoff K; Fischer U
    Oncogene; 2007 Mar; 26(11):1557-66. PubMed ID: 16924230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.